Anthem, the second-biggest health insurer in the doc.ai, is partnering with US and Harvard Medical School researchers on a 12-month innovative study which aims to determine the impact of AI on disease treatment and personalised healthcare. In a statement, Anthem and US acknowledged "data trials that rely on the confluence of blockchain, precision medicine, and artificial intelligence are a fairly new concept". A report by Accenture estimates healthcare's AI market will be worth more than $6bn by 2021.
Anthem, the second-biggest health insurer in the US, is partnering with doc.ai and Harvard Medical School researchers on a 12-month innovative study which aims to determine the impact of AI on disease treatment and personalised healthcare. In a statement, Anthem and doc.ai acknowledged "data trials that rely on the confluence of blockchain, precision medicine, and artificial intelligence are a fairly new concept". A report by Accenture estimates healthcare's AI market will be worth more than $6bn by 2021.